1-8 Recent European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes state that GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide extended release [ER], dulaglutide, efpeglenatide) should be considered for glucose-lowering treatment in patients with T2D at risk of or with heart failure (HF
Once active GLP-1 is secreted, the enzyme DPP-4 quickly cleaves the majority of the hormone 10 and the remaining active GLP-1 enters circulation
Consult a dermatologist before taking it orally or via IV 2
When I started the program, I decided to invest wholeheartedly
Primary antibodies were incubated overnight at 4 C, followed by Alexa Fluor-conjugated secondary antibodies
broad real-world cohorts read lower than trial completers, and the gap is mostly persistence, not a different drug. How do tirzepatide vial sizes compare for common dosing patterns